Skip to content

Study · Measured the body's own peptide · 2022

5 results

Aberrant Expression of Thymosin Beta-4 Correlates With Advanced Disease and BRAF V600E Mutation in Thyroid Cancer.

Kuo CY, Jhuang JY, Huang WC, Cheng SP

The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society1 Oct 2022Cited by 10 (Europe PMC)

PMID36321670 (opens in a new tab)PMCIDPMC9660367 (opens in a new tab)DOI10.1369/00221554221138370 (opens in a new tab)PepBankPUB-36321670
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Natural levels measured5

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelObservational studyOther

    In 141 patients with differentiated thyroid cancer, higher TMSB4X expression was associated with papillary tumor type.

    In plain wordsIn people with thyroid cancer, higher levels of the body's own thymosin beta‑4 were linked to the papillary tumor type.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseTMSB4X expression and papillary tumor type
    Study

    n = 141

    Outcome group
    Cancer biomarkers and prognosis · Cancer

    Source sentences

    Summary
    Among 141 patients with differentiated thyroid cancer, higher TMSB4X expression was associated with papillary tumor type, extrathyroidal extension, lymph node metastasis, and BRAF V600E mutation.
    1 context sentence
    Summary · context
    In the present study, we aimed to study the immunostaining pattern of TMSB4X in benign and malignant thyroid neoplasms.

    This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.

  2. 02HumanEndogenous levelObservational studyOther

    In 141 patients with differentiated thyroid cancer, higher TMSB4X expression was associated with extrathyroidal extension.

    In plain wordsIn people with thyroid cancer, higher levels of the body's own thymosin beta‑4 were linked to tumor spread beyond the thyroid.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseTMSB4X expression and extrathyroidal extension
    Study

    n = 141

    Outcome group
    Cancer biomarkers and prognosis · Cancer

    Source sentences

    Summary
    Among 141 patients with differentiated thyroid cancer, higher TMSB4X expression was associated with papillary tumor type, extrathyroidal extension, lymph node metastasis, and BRAF V600E mutation.
    1 context sentence
    Summary · context
    In the present study, we aimed to study the immunostaining pattern of TMSB4X in benign and malignant thyroid neoplasms.

    This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.

  3. 03HumanEndogenous levelObservational studyOther

    In 141 patients with differentiated thyroid cancer, higher TMSB4X expression was associated with lymph node metastasis.

    In plain wordsIn people with thyroid cancer, higher levels of the body's own thymosin beta‑4 were linked to spread to lymph nodes.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseTMSB4X expression and lymph node metastasis
    Study

    n = 141

    Outcome group
    Cancer biomarkers and prognosis · Cancer

    Source sentences

    Summary
    Among 141 patients with differentiated thyroid cancer, higher TMSB4X expression was associated with papillary tumor type, extrathyroidal extension, lymph node metastasis, and BRAF V600E mutation.
    1 context sentence
    Summary · context
    In the present study, we aimed to study the immunostaining pattern of TMSB4X in benign and malignant thyroid neoplasms.

    This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.

  4. 04HumanEndogenous levelObservational studyOther

    In 141 patients with differentiated thyroid cancer, higher TMSB4X expression was associated with BRAF V600E mutation.

    In plain wordsIn people with thyroid cancer, higher levels of the body's own thymosin beta‑4 were linked to the BRAF V600E mutation.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseTMSB4X expression and BRAF V600E mutation
    Study

    n = 141

    Outcome group
    Cancer biomarkers and prognosis · Cancer

    Source sentences

    Summary
    Among 141 patients with differentiated thyroid cancer, higher TMSB4X expression was associated with papillary tumor type, extrathyroidal extension, lymph node metastasis, and BRAF V600E mutation.
    1 context sentence
    Summary · context
    In the present study, we aimed to study the immunostaining pattern of TMSB4X in benign and malignant thyroid neoplasms.

    This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.

  5. 05HumanEndogenous levelObservational studyOther

    In thyroid tissue, TMSB4X immunostaining was overexpressed in papillary, follicular, poorly differentiated and undifferentiated thyroid cancer, while normal tissue and benign disorders showed undetectable staining.

    In plain wordsIn thyroid samples, the body's own thymosin beta‑4 was much higher in thyroid cancers than in normal or benign thyroid tissue.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseTMSB4X immunostaining in thyroid cancer versus normal and benign thyroid
    Study

    n: not reported in source

    Comparator
    Normal thyroid tissue and benign thyroid disorders
    Outcome group
    Cancer biomarkers and prognosis · Cancer

    Source sentences

    Summary
    By contrast, overexpression of TMSB4X was observed in a variety of thyroid malignancies, including papillary, follicular, poorly differentiated, and undifferentiated thyroid cancer.
    2 context sentences
    Summary · context
    Immunohistochemical analysis revealed that normal thyroid tissue or benign thyroid disorders exhibited undetectable immunoreactivity against TMSB4X except for positive staining of inflammatory infiltrates and stromal cells associated with autoimmune thyroid disease.
    Summary · context
    In the present study, we aimed to study the immunostaining pattern of TMSB4X in benign and malignant thyroid neoplasms.

    This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.